ArticleSignal transduction and targeted therapy2026
Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Despite the paradigm shift brought about by anti-VEGF therapy against neovascular age-related macular degeneration, significant challenges persist, including the risk of intraocular infection and retinal structural damage caused by frequent intravitreal injections, suboptimal long-term outcomes in some patients, as well as economic and psychological burdens. Attempts to identify novel therapeutic targets with more compliant drug delivery strategies are warranted. In this study, we identify that nucleolin (NCL) is upregulated in choroidal neovascularization lesions and mobilized to the endothelial cell surface upon VEGF stimulation. Inspired by this localization change and the critical role of NCL in angiogenesis, we developed an integrated delivery and degradation platform, named dNCL@tFNAs, which leverages tetrahedral framework nucleic acids (tFNAs) to decorate an aptamer-based proteolysis-targeting chimera for NCL through a simple Watson-Crick pairing. dNCL@tFNAs exhibits notable stability, improved ocular penetration and degradation efficiency. Mechanistic study reveals that membrane-associated NCL promotes the uptake of dNCL@tFNAs into the endothelial cells, followed by engaging the cytosolic PROTAC machinery to degrade intracellular NCL via the ubiquitin-proteasome pathway. In vivo study demonstrates that dNCL@tFNAs enables administration via a minimally invasive subconjunctival injection to suppress choroidal neovascularization with a favorable safety profile. Collectively, our work establishes a programmable delivery and degradation modality for the treatment of choroidal neovascularization and other ocular neovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.